Clinical Trial

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Study acronym: NeoART
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is a phase Ib/II, prospective, single arm, open label, non-randomized, multi-center platform trial assessing the feasibility and safety of different neoadjuvant trastuzumab-deruxtecan containing combinational treatment regimens in patients with HER2 positive, locally advanced, resectable esophagogastric adenocarcinoma
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-22
notable Trial sites expanded: 11 -> 14 locations 2026-04-22
Trial Details
NCT Number NCT06731803
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Daiichi Sankyo
Conditions Esophagogastric Adenocarcinoma
Enrollment 36 participants
Start Date 2025-03-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21